Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
The company's proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform harnesses the body's natural base editing system – specifically ADAR (Adenosine Deaminase Acting on RNA) – to make targeted edits to a single RNA base. William Blair notes that ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over- or underexpression of target genes. Also Read: Why Newly Listed Korro Bio Shares Are Gaining Today? William Blair emphasizes that Wave Life Sciences Ltd (NASDAQ: WVE ) is set to release the first clinical data for an ADAR-recruiting therapy in 2024. The analyst initiates with an Outperform rating The data from the Phase 1b/2a RestorAATion-2 trial of WVE-006 for severe Alpha-1 antitrypsin deficiency (A1ATD) will be crucial in determining whether the ADAR-mediated RNA editing mechanism is consistent across species—a key concern for investors due to differences i
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Ltd. (NASDAQ: WVE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $10.00 price target on the stock.MarketBeat
- Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular DystrophyGlobeNewswire
- Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
WVE
Earnings
- 8/8/24 - Miss
WVE
Sec Filings
- 8/23/24 - Form 4
- 8/21/24 - Form 144
- 8/14/24 - Form 4
- WVE's page on the SEC website